KR102328351B1 - 신규한 BRaf 억제제 및 피부 반응의 치료를 위한 이의 용도 - Google Patents

신규한 BRaf 억제제 및 피부 반응의 치료를 위한 이의 용도 Download PDF

Info

Publication number
KR102328351B1
KR102328351B1 KR1020207005707A KR20207005707A KR102328351B1 KR 102328351 B1 KR102328351 B1 KR 102328351B1 KR 1020207005707 A KR1020207005707 A KR 1020207005707A KR 20207005707 A KR20207005707 A KR 20207005707A KR 102328351 B1 KR102328351 B1 KR 102328351B1
Authority
KR
South Korea
Prior art keywords
delete delete
compound
composition
formula
erk
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020207005707A
Other languages
English (en)
Korean (ko)
Other versions
KR20200035990A (ko
Inventor
노아 쉘라슈
Original Assignee
루트리스 파마 엘티디.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 루트리스 파마 엘티디. filed Critical 루트리스 파마 엘티디.
Publication of KR20200035990A publication Critical patent/KR20200035990A/ko
Application granted granted Critical
Publication of KR102328351B1 publication Critical patent/KR102328351B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Cosmetics (AREA)
KR1020207005707A 2017-07-29 2018-07-26 신규한 BRaf 억제제 및 피부 반응의 치료를 위한 이의 용도 Active KR102328351B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762538675P 2017-07-29 2017-07-29
US62/538,675 2017-07-29
PCT/IL2018/050836 WO2019026065A2 (en) 2017-07-29 2018-07-26 NOVEL BRAF INHIBITORS AND THEIR USE FOR THE TREATMENT OF SKIN REACTIONS

Publications (2)

Publication Number Publication Date
KR20200035990A KR20200035990A (ko) 2020-04-06
KR102328351B1 true KR102328351B1 (ko) 2021-11-19

Family

ID=65233550

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020207005707A Active KR102328351B1 (ko) 2017-07-29 2018-07-26 신규한 BRaf 억제제 및 피부 반응의 치료를 위한 이의 용도

Country Status (15)

Country Link
US (3) US10927112B2 (enExample)
EP (1) EP3661515B1 (enExample)
JP (1) JP6912667B2 (enExample)
KR (1) KR102328351B1 (enExample)
CN (1) CN111132680B (enExample)
AU (1) AU2018311538B2 (enExample)
CA (1) CA3070542C (enExample)
DK (1) DK3661515T3 (enExample)
ES (1) ES2908602T3 (enExample)
HR (1) HRP20220609T1 (enExample)
IL (1) IL272312B (enExample)
MX (1) MX383386B (enExample)
SI (1) SI3661515T1 (enExample)
WO (1) WO2019026065A2 (enExample)
ZA (1) ZA202000354B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11458139B2 (en) * 2017-08-08 2022-10-04 Memorial Sloan Kettering Cancer Center Use of BRAF inhibitors for treating cutaneous reactions caused by treatment with a MEK inhibitor
MX2021009535A (es) 2019-02-12 2022-10-10 Lutris Pharma Ltd Uso de composiciones tópicas de inhibidores de braf para el tratamiento de la dermatitis por radiación.
WO2022136912A1 (en) * 2020-12-24 2022-06-30 Lutris Pharma Ltd. Topical braf inhibitor compositions for treatment of egfr downstream effectors - induced reactions
WO2023275620A2 (en) * 2021-07-02 2023-01-05 Lutris Pharma Ltd. Use of isoquinoline-1,5-diamines for wound healing

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130226549A1 (en) 2012-02-27 2013-08-29 Yufeng J. Tseng Structure-based fragment hopping for lead optimization and improvement in synthetic accessibility
US20140005198A1 (en) 2007-06-07 2014-01-02 Amgen Inc. Raf kinase modulators and methods of use
US20170100345A1 (en) 2014-05-06 2017-04-13 The Regents Of The University Of California Wound healing using braf inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5753612A (en) 1992-10-27 1998-05-19 Yissum Research Development Co. Of The Hebrew University Of Jerusalem Pharmaceutical composition and method for inhibiting hair growth by administration of activin or activin agonists
US7989461B2 (en) 2005-12-23 2011-08-02 Amgen Inc. Substituted quinazolinamine compounds for the treatment of cancer
KR20140011780A (ko) 2012-07-19 2014-01-29 한미약품 주식회사 단백질 키나아제 저해활성을 갖는 이소퀴놀린-5-카복스아미드 유도체
RU2015149937A (ru) * 2013-05-30 2017-07-06 Плексксикон Инк. Соединения для модулирования киназы и показания к их применению
CN109069511A (zh) 2016-03-10 2018-12-21 鲁特里斯制药有限公司 Braf抑制剂用于治疗皮肤反应的用途

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140005198A1 (en) 2007-06-07 2014-01-02 Amgen Inc. Raf kinase modulators and methods of use
US20130226549A1 (en) 2012-02-27 2013-08-29 Yufeng J. Tseng Structure-based fragment hopping for lead optimization and improvement in synthetic accessibility
US20170100345A1 (en) 2014-05-06 2017-04-13 The Regents Of The University Of California Wound healing using braf inhibitors

Also Published As

Publication number Publication date
JP2020528933A (ja) 2020-10-01
ES2908602T3 (es) 2022-05-03
JP6912667B2 (ja) 2021-08-04
BR112020001935A2 (pt) 2020-07-28
ZA202000354B (en) 2024-01-31
RU2020108782A3 (enExample) 2021-09-02
WO2019026065A2 (en) 2019-02-07
US20210070757A1 (en) 2021-03-11
EP3661515B1 (en) 2022-02-23
KR20200035990A (ko) 2020-04-06
CA3070542C (en) 2021-05-18
HRP20220609T1 (hr) 2022-06-24
CA3070542A1 (en) 2019-02-07
MX383386B (es) 2025-03-13
CN111132680B (zh) 2022-02-08
EP3661515A2 (en) 2020-06-10
CN111132680A (zh) 2020-05-08
EP3661515A4 (en) 2021-01-06
AU2018311538B2 (en) 2021-03-25
DK3661515T3 (da) 2022-04-19
SI3661515T1 (sl) 2022-06-30
AU2018311538A1 (en) 2020-02-13
RU2020108782A (ru) 2021-09-02
US20190389862A1 (en) 2019-12-26
IL272312B (en) 2021-06-30
US11339163B2 (en) 2022-05-24
US10927112B2 (en) 2021-02-23
IL272312A (en) 2020-03-31
WO2019026065A3 (en) 2019-08-01
US20220274988A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US20220274988A1 (en) Braf inhibitors and use thereof for treatment of cutaneous reactions
KR101839915B1 (ko) 아릴아미노 퓨린 유도체, 그의 제조 방법 및 약학적 용도
KR102598775B1 (ko) Ｒｏｒ­감마 조절제
EP2197851B1 (en) Derivatives of n-phenylacetamide as inhibitors of the enzyme soat1 for pharmaceutical and cosmetic use
CN104411685A (zh) 3-o-杂芳基-巨大戟二萜醇
KR101792402B1 (ko) 니코틴산 아데닌 디뉴클레오티드 인산 및 그 유도체를 포함하는 발모 또는 육모 촉진제
KR20250164150A (ko) 장 또는 복통 치료를 위한 누트카톤
RU2779185C2 (ru) Новые ингибиторы braf и их применение для лечения кожных реакций
TWI308148B (en) Novel compound of 6-methyl-3-phenethyl-3,4-dihydro-1h-quinazoline-2-thione, its preparation and a depigmentation composition containing the same as an effective component
WO2004082683A1 (ja) 慢性皮膚疾患の治療および／または予防剤
EP4267144B1 (en) Topical BRAF inhibitor compositions for the treatment of reactions induced by downstream EGFR effectors
JPWO2006041120A1 (ja) 医薬組成物
BR112020001935B1 (pt) Novos inibidores de braf e uso destes para o tratamento de reações cutâneas
JP5792318B2 (ja) ブロムフェナク有機塩、ならびにその製造方法、組成物および使用
EP4720079A1 (en) Mitochondria specific transcription inhibitors
KR20180071537A (ko) 신규한 화합물 및 이의 용도
KR20250018227A (ko) 이소니코틴산을 포함하는 피부 건강 개선용 조성물
KR101511857B1 (ko) 디메틸 칸타리딘을 유효성분으로 포함하는 체모성장 저해용 조성물
CN109776373A (zh) 酰胺取代的吡咯烷酰胺衍生物及其用途
WO2006123726A1 (ja) 医薬組成物
WO2011090357A2 (ko) 신규한 바이아릴아미드 유도체 및 이를 유효성분으로 함유하는 조성물

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20200226

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
A302 Request for accelerated examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20201216

Comment text: Request for Examination of Application

PA0302 Request for accelerated examination

Patent event date: 20201216

Patent event code: PA03022R01D

Comment text: Request for Accelerated Examination

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20210407

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20210819

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20211115

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20211115

End annual number: 3

Start annual number: 1

PG1601 Publication of registration